Researchers review Real-World use of avelumab in advanced bladder cancer
NCT ID NCT06412848
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study reviews medical records of 360 Japanese patients with advanced bladder cancer who received avelumab as a maintenance treatment after initial chemotherapy. The goal is to understand patient characteristics, treatment patterns, and outcomes like survival and tumor response. No new treatments are given; it simply observes what happened in real-world practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akita University Hospital
Akita, 010-0041, Japan
-
Ehime University Hospital
Tōon, Ehime, 791-0295, Japan
-
Hirosaki University Hospital
Hirosaki, Aomori, 036-8563, Japan
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
Iwate Medical University Hospital
Shiwa-gun, Iwate, 028-3695, Japan
-
Juntendo University Hospital
Bunkyō City, Tokya, 113-0033, Japan
-
Kagawa University Hospital
Kita-gun, Kagawa-ken, 761-0793, Japan
-
Kindai University Hospital
Sayama, Osaka, 589-8511, Japan
-
Kitasato University Hospital
Sagamihara, Kanagawa, 252-0374, Japan
-
Kobe University Hospital
Kobe, Hyōgo, 650-0017, Japan
-
Kumamoto University Hospital
Kumamoto, 860-8556, Japan
-
Kurume University Hospital
Kurume, Fukuoka, 830-0011, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
Kyushu Cancer Center
Fukuoka, 811-1347, Japan
-
Nara Medical University Hospital
Kashihara, Nara, 634-8522, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
Nippon Medical School Hospital
Bunkyo-ku, Tokyo, 113-8603, Japan
-
Osaka International Cancer Institute
Osaka, 540-0008, Japan
-
Saitama Medical University International Medical Center
Hidaka, Saitama, 350-1298, Japan
-
Sapporo Medical University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
St. Marianna University Hospital
Kawasaki, Kanagawa, 216-8511, Japan
-
Teikyo University Hospital
Itabashi-ku, Tokyo, 173-8606, Japan
-
Tokushima University Hospital
Tokushima, 770-0042, Japan
-
Toyama University Hospital
Toyama, 930-0194, Japan
-
University Hospital Kyoto Prefectural University of Medicine
Kyoto, 602-8566, Japan
-
Yamagata University Hospital
Yamagata, 9902331, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New antibody aims to unlock immune attack on Hard-to-Treat cancers